Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology
Rebecca Smausz, Joanna C. Neill, John Gigg
Journal of Psychopharmacology (2022) Vol. 36, Iss. 7, pp. 781-793
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
M. Ishrat Husain, Nicole Ledwos, Elise Fellows, et al.
Frontiers in Psychiatry (2023) Vol. 13
Open Access | Times Cited: 30
5-HT2AR and NMDAR psychedelics induce similar hyper-synchronous states in the rat cognitive-limbic cortex-basal ganglia system
Ivani Brys, Sebastián A. Barrientos, Jon Ezra Ward, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 16
Mitochondrial Metabolism in Major Depressive Disorder: From Early Diagnosis to Emerging Treatment Options
Ane Larrea, Laura Sánchez-Sánchez, Eguzkiñe Díez-Martín, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1727-1727
Open Access | Times Cited: 7
Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers
Juliana Lima Constantino, Jens H. van Dalfsen, Sara Massetti, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025) Vol. 136, pp. 111251-111251
Open Access
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity
Daniel A Kinderlehrer
Neuropsychiatric Disease and Treatment (2025) Vol. Volume 21, pp. 141-155
Open Access
Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications
Taynah Pereira Galdino, Lucas Cordeiro de Oliveira, Mateus Araújo da Luz, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 380-380
Open Access
Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives
Sung‐Hyun Kim, Sumin Yang, Jeehye Jung, et al.
Advanced Science (2025)
Open Access
Leveraging the Metaverse for Enhanced Longevity as a Component of Health 4.0
Srinivasan S. Pillay, Patrick Candela, Ivana T. Croghan, et al.
Mayo Clinic Proceedings Digital Health (2024) Vol. 2, Iss. 1, pp. 139-151
Open Access | Times Cited: 4
Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases
Zarah R. Haniff, Mariia Bocharova, Tim Mantingh, et al.
Pharmacology & Therapeutics (2024) Vol. 258, pp. 108641-108641
Open Access | Times Cited: 4
The evolution and ecology of psilocybin in nature
Matthew J. Meyer, Jason C. Slot
Fungal Genetics and Biology (2023) Vol. 167, pp. 103812-103812
Closed Access | Times Cited: 9
Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review
James J Gattuso, Carey Wilson, Anthony J. Hannan, et al.
Journal of Neurochemistry (2023)
Open Access | Times Cited: 8
Decoupling of cortical activity from behavioral state following administration of the classic psychedelic DOI
Randall J. Olson, Lowell Bartlett, Alex Sonneborn, et al.
Neuropharmacology (2024) Vol. 257, pp. 110030-110030
Closed Access | Times Cited: 1
Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials
Sepehr Aghajanian, Arman Shafiee, Samira Parvizi Omran, et al.
Journal of Psychopharmacology (2024)
Closed Access | Times Cited: 1
Psilocybin as a novel treatment for chronic pain
Tate Askey, Reena Lasrado, Maria Maiarù, et al.
British Journal of Pharmacology (2024)
Closed Access | Times Cited: 1
Systems-level analysis of local field potentials reveals differential effects of lysergic acid diethylamide and ketamine on neuronal activity and functional connectivity
Azat Nasretdinov, Sebastián A. Barrientos, Ivani Brys, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 2
Potential use of psilocybin drugs in the treatment of depression
Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 4, pp. 241-256
Closed Access | Times Cited: 2
If psychedelics heal, how do they do it?
Carolyn Beans
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 2
Open Access
Los hongos alucinógenos (Psilocybe, Hymenogastraceae) en el desarrollo evolutivo de la consciencia del hombre
Jehoshua Macedo-Bedoya, Fatima Calvo-Bellido
Lilloa (2024), pp. 27-38
Open Access
The influence of psilocybin on subconscious and conscious emotional learning
Andrea Casanova, Andres Ort, John Smallridge, et al.
iScience (2024) Vol. 27, Iss. 6, pp. 110034-110034
Open Access
Licit use of illicit drugs for treating depression: the pill and the process
Alejandro Torrado Pacheco, Bita Moghaddam
Journal of Clinical Investigation (2024) Vol. 134, Iss. 12
Open Access
Rapid and prolonged antidepressant and antianxiety effects of psychedelics and 3, 4-methylenedioxy-methamphetamine. A systematic review and meta-analysis
Dimy Fluyau, Vasanth Kattalai Kailasam, Neelambika Revadigar
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
Nauman Ashraf
Journal of Pakistan Psychiatric Society (2024) Vol. 21, Iss. 02
Open Access
Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression
Joshua M. Poulin, Gregory E. Bigford, Krista L. Lanctôt, et al.
Trials (2024) Vol. 25, Iss. 1
Open Access
Renaissance der Psychedelika
Dirk Netter, Fabian P. Steinmetz
Springer eBooks (2024), pp. 219-234
Closed Access
Voltage-gated potassium channels as a potential therapeutic target for the treatment of neurological and psychiatric disorders
Isabel E Faulkner, Rachael Z Pajak, Michael Harte, et al.
Frontiers in Cellular Neuroscience (2024) Vol. 18
Open Access
Page 1 - Next Page

Scroll to top